DelveInsight’s, “Nosocomial Pneumonia Pipeline Insight, 2023,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in the Nosocomial Pneumonia pipeline landscape. It covers the Nosocomial Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nosocomial Pneumonia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Nosocomial Pneumonia Pipeline Report

• DelveInsight’s Nosocomial Pneumonia pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Nosocomial Pneumonia treatment.
• The leading companies working in the Nosocomial Pneumonia Market include Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Promising Nosocomial Pneumonia Pipeline Therapies in the various stages of development include Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
• October 2023: Merck Sharp & Dohme LLC announced a study of Phase 1 clinical trials for Ceftolozane/Tazobactam. This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP). A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia.
• August 2023: Pfizer announced a study of Phase 4 clinical trials for Zavicefta, Ceftazidime-Avibactam. This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.
• May 2023: Basilea Pharmaceutical announced a study of Phase 3 clinical trials for Ceftobiprole medocaril. This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy. A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation.

 

Request a sample and discover the recent advances in Nosocomial Pneumonia Treatment Drugs @ Nosocomial Pneumonia Pipeline Report

 

In the Nosocomial Pneumonia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Nosocomial Pneumonia Overview

Nosocomial pneumonia or hospital-acquired pneumonia (HAP) is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. HAP occurs at a rate of 5 to 10 per 1000 hospital admissions and is considered the most common cause of hospital-acquired infection in Europe and the United States.

 

Find out more about Nosocomial Pneumonia Therapeutics Assessment @ Nosocomial Pneumonia Preclinical and Discovery Stage Products

 

Nosocomial Pneumonia Emerging Drugs Profile

• Tosatoxumab: Aridis Pharmaceuticals
• Suvratoxumab: AstraZeneca
• Rifabutin: BioVersys
• CMTX 101 : Clarametyx Biosciences

 

Nosocomial Pneumonia Pipeline Therapeutics Assessment

There are approx. 13+ key companies which are developing the Nosocomial Pneumonia therapies. The Nosocomial Pneumonia companies which have their Nosocomial Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.

 

DelveInsight’s Nosocomial Pneumonia Pipeline Report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Nosocomial Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Nosocomial Pneumonia Pipeline Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Learn more about the emerging Nosocomial Pneumonia Pipeline Therapies @ Nosocomial Pneumonia Clinical Trials Assessment

 

Scope of the Nosocomial Pneumonia Pipeline Report

• Coverage- Global
• Nosocomial Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nosocomial Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Nosocomial Pneumonia Companies- Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Nosocomial Pneumonia Pipeline Therapies- Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.

 

Dive deep into rich insights for new drugs for Nosocomial Pneumonia Treatment, Visit @ Nosocomial Pneumonia Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Nosocomial Pneumonia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nosocomial Pneumonia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tosatoxumab: Aridis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Suvratoxumab: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Rifabutin : BioVersys
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CMTX 101 : Clarametyx Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nosocomial Pneumonia Key Companies
21. Nosocomial Pneumonia Key Products
22. Nosocomial Pneumonia- Unmet Needs
23. Nosocomial Pneumonia- Market Drivers and Barriers
24. Nosocomial Pneumonia- Future Perspectives and Conclusion
25. Nosocomial Pneumonia Analyst Views
26. Nosocomial Pneumonia Key Companies
27. Appendix

 

For further information on the Nosocomial Pneumonia Pipeline therapeutics, reach out to Nosocomial Pneumonia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting